Celyad Oncology SA
CYAD | BR
Overview
Corporate Details
- ISIN(s):
- BE0974260896 (+2 more)
- LEI:
- 549300ORR0M8XF56OI64
- Country:
- Belgium
- Address:
- RUE ANDRE DUMONT 9, 1435 MONT-SAINT-GUIBERT
- Website:
- https://celyad.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Celyad Oncology SA is a clinical-stage biotechnology company specializing in the discovery and development of Chimeric Antigen Receptor (CAR) T-cell therapies for cancer. The company focuses on creating innovative technology platforms and CAR T-cell candidates designed to overcome the limitations of existing treatments and expand their application to a broader range of cancer types. Its research pipeline includes both allogeneic (off-the-shelf) and autologous (patient-specific) candidates targeting hematological malignancies and solid tumors. A core component of the company's strategy is the monetization of its proprietary technologies and intellectual property.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Celyad Oncology SA.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2024-09-16 00:00 |
Board/Management Information
20240916_CYAD_PR_new-CEO-ENG (1).pdf
|
English | 85.6 KB | |
| 2024-09-16 00:00 |
Board/Management Information
20240916_CYAD_PR_new-CEO-FR (1).pdf
|
French | 93.8 KB | |
| 2024-09-15 14:00 |
Interim Report
06082024_Celyad - Financial Report H1-2024 - EN.pdf
|
English | 852.9 KB | |
| 2024-09-15 14:00 |
Interim Report
Celyad Oncology - RAPPORT FINANCIER INTERMEDIAIRE_2024 - FR.pdf
|
French | 1.2 MB | |
| 2024-05-06 19:00 |
Share Issue/Capital Change
AGEx Ceyad Oncology 6 mai 2024 - signatures digitales.pdf
|
French | 2.5 MB | |
| 2024-05-06 18:00 |
Post-Annual General Meeting Information
PV AGO Ceyad Oncology 6 mai 2024 - signé - FR.pdf
|
French | 1.4 MB | |
| 2024-04-05 08:00 |
Pre-Annual General Meeting Information
CELYAD-AGO-et-AGE-mai-2024-Informations-aux-actionnaires-FR.Final_.pdf
|
French | 118.8 KB | |
| 2024-04-05 08:00 |
Legal Proceedings Report
Rapport_Special_CA_pour_AGE_Sonnette_dalarme_-_2024_-_FR.signed.pdf
|
French | 294.9 KB | |
| 2024-04-05 08:00 |
Registration Form
Celyad-Oncology-coord.-ENG-06.05.2024.pdf
|
English | 361.3 KB | |
| 2024-04-05 08:00 |
Registration Form
Celyad-Oncology-coord.-FR-06.05.2024.pdf
|
French | 225.1 KB | |
| 2024-04-05 08:00 |
Share Issue/Capital Change
Warrant-Plan-2024-ENG.final_.pdf
|
English | 208.7 KB | |
| 2024-04-05 08:00 |
Remuneration Information
Warrant-Plan-2024-FR.final_.pdf
|
French | 258.5 KB | |
| 2024-04-05 08:00 |
Pre-Annual General Meeting Information
CELYAD-AGM-EGM-May-2024-Information-to-shareholders-ENG.Final_.pdf
|
English | 122.4 KB | |
| 2024-04-05 08:00 |
Proxy Solicitation & Information Statement
CELYAD-AGO-et-AGE-mai-2024-Procuration-personnes-physiques-FR-ENG.pdf
|
French | 469.6 KB | |
| 2024-04-05 08:00 |
Pre-Annual General Meeting Information
Special_Report_Board_to_AGEX_Alarm_bell_2024_-_ENG.signed.pdf
|
English | 329.9 KB |
Automate Your Workflow. Get a real-time feed of all Celyad Oncology SA filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Celyad Oncology SA via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-11-28 | Kane Matthew | Board | Other | 1,035,714 | 279,642.78 EUR |
| 2024-11-26 | Piscitelli Dominic | Board | Other | 10,000 | 2,700.00 EUR |
| 2024-11-25 | Iserentant Hannes | Executive member | Other | 30,000 | 8,100.00 EUR |
| 2024-11-22 | Phan An | Executive member | Other | 30,000 | 8,100.00 EUR |
| 2024-11-06 | Goblet Serge | Board | Other | 10,000 | 2,700.00 EUR |
| 2024-11-05 | Udier Blagovic Marina | Board | Other | 10,000 | 2,700.00 EUR |
